Osteoporosis
Findings from Finland, Denmark and the United States in osteoporosis provide new insights
Published in Women's Health Weekly, October 5th, 2006
Study 1: The effectiveness of ospemifene as bone-restoring therapy appears comparable to that of raloxifene.
Researchers in Finland report, "Ospemifene is a novel selective estrogen receptor modulator (SERM) that is initially being developed for the treatment of vaginal atrophy in postmenopausal women. However, it also shows promise in the prevention and treatment of osteoporosis."
"As a part of a phase II trial, we compared the effects of ospemifene and raloxifene on bone turnover in postmenopausal women," wrote J. Komi and colleagues...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Boost radiotherapy decreases risk of local relapse in women with ductal carcinoma in situ - Breast Cancer
Breast cancer prediction by volatile breath biomarkers may be promising screening modality - Breast Cancer
Timely initiation of radiation therapy after breast cancer surgery may improve survival - Human Papillomavirus
HPV prevalence in U.S. is high even among women with one lifetime sexual partner - Migraines
Women with migraines do not appear to have increased occurrence of cardiovascular events - Anemia
Researchers find a relationship between anemia and impaired thinking - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
